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Antibody variable regions are composed of a heavy and a light chain, and in humans,
there are two light chain isotypes: kappa and lambda. Despite their importance in
receptor editing, the light chain is often overlooked in the antibody literature, with the
focus being on the heavy chain complementarity-determining region (CDR)-H3 region.
In this paper, we set out to investigate the physicochemical and structural differences
between human kappa and lambda light chain CDR regions. We constructed a dataset 
containing over 29,000 light chain variable region sequences from IgM-transcribing,
newly formed B cells isolated from human bone marrow and peripheral blood. We also 
used a published human naïve dataset to investigate the CDR-H3 properties of heavy
chains paired with kappa and lambda light chains and probed the Protein Data Bank to 
investigate the structural differences between kappa and lambda antibody CDR regions. 
We found that kappa and lambda light chains have very different CDR physicochemical 
and structural properties, whereas the heavy chains with which they are paired do not
differ significantly. We also observed that the mean CDR3 N nucleotide addition in the
kappa, lambda, and heavy chain gene rearrangements are correlated within donors but 
can differ between donors. This indicates that terminal deoxynucleotidyl transferase may 
work with differing efficiencies between different people but the same efficiency in the
different classes of immunoglobulin chain within one person. We have observed large
differences in the physicochemical and structural properties of kappa and lambda light 
chain CDR regions. This may reflect different roles in the humoral immune response.
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inTrODUcTiOn
Immunoglobulins are a crucial component of the humoral immune system. They are Y-shaped 
heterodimeric proteins expressed by B cells that are composed of two identical heavy chains and 
two identical light chains. They can be cell-surface bound as B cell receptors (BCRs) or released into 
the extracellular environment as antibodies. There is enormous diversity in the immunoglobulin 
repertoire, which is required to facilitate recognition of a wide variety of different antigen challenges.
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Variability in the antigen-binding sites is achieved by V(D)J 
recombination, combinatorial diversity via heavy and light chain 
pairing, and the post-activation processes of somatic hypermu-
tation and class switching. There are five heavy chain isotypes 
(IgM, IgD, IgG, IgE, and IgA), which confer different antibody 
functions, and two light chain isotypes (kappa and lambda). The 
most diverse immunoglobulin regions are the six hypervariable 
complementarity-determining region (CDR) loops, which are 
held in place by the structural beta-sheet framework regions (FRs) 
(1). The CDR-H3 has a particularly high diversity, arising from a 
combination of IGHD gene inclusion, extra nucleotide addition 
by terminal deoxynucleotidyl transferase (TdT), and imprecise 
joining of the gene segments (2). CDR-H3 is often considered 
to be the main protein loop involved in antibody specificity (3, 
4), and this region can be considered a fingerprint for the B cell 
and its progeny. The CDR-L3 region is similarly diverse, although 
without the contribution from a D gene, the degree of variability 
is less. However, light chains can also be important for the binding 
specificity of antibodies; light chains are swapped during receptor 
editing to change the specificity of the antibody (5, 6). Hence, the 
contribution of light chains to the antigen-binding sites must not 
be overlooked.
The genes encoding the two light chain isotypes are located 
on separate chromosomes. Kappa gene segments are encoded 
on chromosome 2 (7) comprising 52 V genes and 5 J genes (8), 
whereas lambda gene segments are encoded on chromosome 
22 (9) comprising 30 V genes and 7 J genes (10). Kappa locus 
rearrangement usually precedes the rearrangement of the lambda 
locus (11), and there are more kappa antibodies in the human 
peripheral blood, with the kappa/lambda ratio reported to be 
between approximately 1.5 and 2 (12–14). However, in antigen-
selected populations, this ratio can differ significantly depend-
ing on the class of antibody heavy chain (15). As an example, 
antibodies in mucosal secretions (predominantly IgA) have been 
reported as being mostly lambda (12).
Broad phenotypic differences, such as conformational 
flexibility (16), half-life (14), and propensity to alter antibody 
specificity (17), have been noted between antibodies bearing 
kappa or lambda light chains. There are also reports of altered 
kappa:lambda ratios being characteristic of certain diseases 
(18). Notably, it has recently been shown that in chronic HIV 
patients, HIV Env-specific antibodies have a very strong bias 
in favor of the lambda light chain (19). Hence, we hypothesize 
that differential use of kappa and lambda light chains may lead 
to differing binding specificities, and this may be indicated by 
inherently different characteristics in the binding regions of the 
two light chain isotypes.
We have used long read high-throughput sequencing to obtain 
29,447 human light chain variable region sequences from antigen-
inexperienced cells in order to investigate potential differences 
between kappa and lambda antigen-binding sites. We compared 
the kappa and lambda CDR-L3 regions and discovered large, 
highly significant differences in the physicochemical properties, 
which were largely encoded in the germline IGLV and IGLJ gene 
segments. Inclusion of CDR-H3 in the analysis indicates that a 
correlation between N region additions in all Ig gene rearrange-
ments exists within an individual, but that there is interindividual 
variation, suggesting variation in TdT activity. Additionally, we 
have used published human paired heavy and light chain variable 
sequences (20) to investigate the CDR-H3 properties of heavy 
chains paired with kappa or lambda light chains and shown that 
the pairing of heavy and light chain has very little, if any, bias. 
To assess whether structural differences exist between kappa 
and lambda light chains, we analyzed antibody structures in the 
Protein Data Bank (PDB) and observed significant differences in 
the secondary structure content of the light chain CDR regions.
MaTerials anD MeThODs
sample collection
Bone marrow and peripheral blood was collected from 19 healthy 
donors, aged 24–86, with no known autoimmune disease, under-
going hip replacement surgery at Guy’s Hospital, London, UK 
(REC# 11/LO/1266).
extracting lymphocytes from Bone 
Marrow
The bone marrow matrix was removed from the head of the 
femur by scraping. Cells were washed out of the bone cavity using 
BM isolation buffer (10 mM EDTA, 2% (v/v) HI-FCS, 1× dPBS, 
pH 7.4). The sample was transferred to a 50-ml Falcon tube. The 
volume was made up to 35  ml using BM isolation buffer and 
mixed by inverting the tube. The mixture was passed through a 
100-μm cell strainer (Falcon) into a clean 50-ml Falcon tube. The 
strained solution was carefully layered onto 15-ml Ficoll (room 
temperature) and the lymphocytes layered by centrifugation at 
400 g for 35 min (no brake). The lymphocyte layer was removed 
into a clean 50-ml Falcon tube and washed once in BM isolation 
buffer, collecting by centrifugation at 300 g for 10 min, and once 
in 1-ml RPMI suspension buffer (10% HI-FCS, RPMI 1640) in a 
1.5-ml microcentrifuge tube, collecting by centrifuging in micro-
centrifuge at 2 × 1,000 for 5 min. The pellet was re-suspended in 
1-ml RPMI suspension buffer, and cells were counted. Cells were 
frozen overnight in HI-FCS, 10% DMSO at −80°C (Mr. Frosty 
Freezing Container, Thermo Scientific) before storing in liquid 
nitrogen until use.
extracting lymphocytes from Peripheral 
Blood
Ten milliliters of peripheral blood was diluted 1:2 using RPMI 
suspension buffer. Thirty milliliters of blood suspension was 
carefully layered onto 15-ml Ficoll in a 50-ml LeucoSep tube 
(Greiner). After centrifugation at 448 g, 20 min (no brake), the 
lymphocyte layer was removed into a clean 50-ml Falcon tube. 
Washing in 10-ml RPMI suspension media (centrifugation at 
275 g, 10 min) was performed twice. Cells were re-suspended in 
RPMI suspension media, counted, and stored as above.
B cell isolation and sorting
Bone marrow CD19+ B cells were enriched to >98% using anti-
human CD19 MicroBeads (Miltenyi Biotec) according to the 
manufacturer’s protocol. B cell suspensions were blocked (RPMI, 
10% normal mouse serum) and subsequently stained using the 
following antibodies: PE anti-human Ig light chain lambda (MHL-
38, Biolegend), APC anti-human Ig light chain kappa (MHK-49, 
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Biolegend), PE/Cy7 anti-human CD38 (HIT2, Biolegend), 
PerCP/Cy5.5 anti-human IgD (IA6-2, Biolegend), Pacific Blue 
anti-human IgM (MHM-88, Biolegend), APC/Cy7 anti-human 
CD10 (HI10a, Biolegend), and CD27-FITC (M-T271, Miltenyi 
Biotec). The FACS Aria (BD Biosciences) was used to isolate 
pre-B and immature B cells (IgM+IgD−CD38+CD27−CD10+) 
directly into Sort Lysis Reverse Transcription (SLyRT) buffer (21). 
These two types of B cell were analyzed collectively as “immature 
B cells” henceforth.
Peripheral blood mononuclear cells (PBMCs) were stained 
using APC anti-human CD19 (HIB19, BD Bioscience), PerCP/
Cy5.5 anti-human IgD (IA6-2, Biolegend), APC/Cy7 anti-human 
CD10 (HI10a, Biolegend), and CD27-FITC (M-T271, Miltenyi 
Biotec). The FACS Aria was used to sort naïve (IgD+CD27−CD10−) 
and transitional (IgD+CD27−CD10+) B cells directly into SlyRT 
buffer.
FACS plots illustrating the cell sorting are available in Martin 
et al. (In Review).1
high-Throughput sequencing  
and sequence analysis
Heavy and light chain variable region cDNA was reverse tran-
scribed from cells in SlyRT buffer, and donor-distinguishing 
multiplex identifiers (MIDs) were added using semi-nested PCR 
as described previously (22). Sequencing was carried out on the 
Roche 454 Titanium platform by LGC Genomics (Germany). 
Data clean-up was then carried out as previously published (22). 
Heavy and light chain variable region sequences were not paired. 
The heavy and light chain sequencing data are available from the 
Sequence Read Archive (accession number SRP081849).
Sequences then underwent immunoglobulin (Ig) genotyping. 
Ig gene usage and the CDR amino acid sequences were deter-
mined using International Immunogenetics Information System 
(IMGT) HighV-QUEST (23). The R (24) package Peptides (25) 
was used to determine the physicochemical properties of CDR 
peptide sequences. Following IMGT definitions, CDR-H3/-L3 
regions were defined as amino acid positions 105–117, CDR-L1: 
positions 27–38 and CDR-L2: positions 56–65 (26).
Clonotype clustering was carried out on CDR3 regions using 
the following protocol. Data were split into V family subsets, and 
the CDR3 nucleotide sequences were used to generate a simple 
Levenshtein edit distance matrix of all possible pairwise com-
parisons. The distance matrix was then hierarchically clustered 
(complete linkage) and the dendrograms cut at 0.05 to release 
branches that constitute the clones. Scripts which illustrate the 
clustering used are available at http://www.bcell.org.uk. Once the 
clusters of related sequences were established, the modal sequence 
was identified to be used as a representative of this group and was 
assigned as a reference sequence. Only the reference sequences 
were used within this analysis to remove any skewing that could 
have arisen from PCR amplification and ensure that we did not 
double-count any duplicates arising from multiple mRNA copies.
1 Martin MG, Wu YCB, Townsend CL, Lu GH, Silva O’hare J, Mozeika A, et al. 
Transitional B cells in early human B cell development – time to revisit the para-
digm? Front Immunol (In Review).
Data were stored in a Microsoft Excel spreadsheet, and sta-
tistical analyses were performed using Microsoft Excel, R 3.2.1 
(24), and GraphPad PRISM version 6.07 for Windows, GraphPad 
Software, La Jolla, CA, USA, www.graphpad.com.
The heavy and light chain master data files can be found at 
http://www.bcell.org.uk.
analysis of Kappa and lambda light 
chain cDr Physicochemical Properties
Data from all 19 donors were pooled. The dataset was cleaned 
by removing entries where the CDR-L3 region was longer than 
20 amino acids (highly unlikely to be correct CDR-L3 calling 
by IMGT HighV-QUEST) or were identified by IMGT HighV-
QUEST as unproductive. The final dataset contained 20,571 
kappa and 8,876 lambda entries (Supplementary Table 1 in the 
Supplementary Data Sheet). The data were analyzed by cell 
type and by kappa and lambda isotype. Cumulative frequency 
histograms were drawn for a variety of CDR-L3 physicochemical 
properties. The Kolmogorov–Smirnov test (KS test) was used to 
evaluate differences in the distributions of properties calculated 
for the kappa and lambda CDR-L3 regions. Multiple t-tests, fol-
lowed by false discovery rate (FDR) correction for multiple test-
ing (Q = 1%), were conducted to measure significant differences 
in amino acid usage.
Principal component analysis (PCA) was performed using the 
10 Kidera factors (27) of the CDR-L3 amino acid sequence. PCA 
was performed using the prcomp function in R.
The physicochemical properties of the kappa and lambda 
CDR-L1 and CDR-L2 regions were also calculated. The CDR-
L1 dataset contained 19,413 kappa and 8,419 lambda entries; 
the CDR-L2 dataset contained 20,004 kappa and 8,631 lambda 
entries.
The datasets used in these analyses can be found at http://
www.bcell.org.uk.
heavy chain antibody Variable  
region Dataset
We only obtained heavy chain data from 12 of the 19 donors. As 
with the light chains, the dataset was cleaned by removing entries 
where the CDR-H3 region was longer than 35 amino acids or was 
identified by IMGT HighV-QUEST as being unproductive. The 
final dataset contained 29,016 entries (Supplementary Table 1 in 
the Supplementary Data Sheet).
construction of Theoretical  
“germline cDr-l3” regions
IMGT Protein displays (28) were used to obtain the amino acid 
sequences for the 5′ end (position 105 onward) of each germline 
*01 allele IGLV and the first 2 3′ amino acids of each germline 
*01 allele IGLJ. The frequency of recombination of different IGLV 
and IGLJ genes in the real dataset was determined. The 5′ IGLV 
amino acid sequences and 3′ IGLJ amino acid sequences were 
then combined at an equivalent frequency, thus producing a 
dataset that is reflective of the original dataset, but only contain-
ing theoretical “germline CDR-L3” region amino acid sequences 
(i.e., CDR-L3 regions encoded by the germline IGLV region and 
germline IGLJ region, with no random nucleotide addition/
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deletion by TdT). Four hundred twenty entries were removed due 
to stop codons in the CDR-L3 regions or “not localized” (NL) 
genes in the dataset. The final dataset contained 20,379 kappa 
and 8,648 lambda entries. The physicochemical properties of 
each theoretical “germline CDR-L3” amino acid sequence were 
calculated. The physicochemical properties of the “germline” and 
real CDR-L3 regions were compared using the statistical analyses 
described above.
analysis of Paired heavy–light chain 
Dataset from the literature
As our dataset contained no heavy–light chain pairing infor-
mation, we used a recently published dataset (20), which was 
generated by the Georgiou lab using their innovative technique 
for paired heavy–light chain sequencing (29, 30). This dataset 
consisted of paired heavy and light chain information from the 
naïve repertoires of three donors. We calculated the physico-
chemical properties of these CDR-H3 regions. We then removed 
any sequences where the CDR-H3 region was >35 amino acids 
long or the sequence lacked light chain information or IGHV/
IGHJ assignments. The resulting datasets from the three donors 
contained 13,771 (Donor 1), 26,343 (Donor 2), and 15,193 (Donor 
3) sequences. Comparison of the CDR-H3 physicochemical 
properties of kappa and lambda antibodies was then conducted 
using the statistical analyses described above.
Protein Data Bank structural analysis
SAbDab (31) was used to build kappa and lambda datasets of 
human structures from the PDB (32), which had been solved 
by X-Ray diffraction at a resolution of less than 3Å. Only paired 
Ig structures (with both heavy and light chains present) were 
considered. PDB entries were subsequently culled using PISCES 
(33), according to a maximum mutual sequence identity of 99% 
to eliminate redundancy.
From this, datasets of 199 kappa and 106 lambda structures 
were obtained. CDR analyses were carried out on these datasets; 
however, due to incomplete CDR information in six PDB struc-
tures (4LSQ, 4OB5, 4Y5Y, 4HKX, 5D70, and 7FAB), kappa anti-
body CDR-H1, lambda antibody CDR-H2, and lambda antibody 
CDR-L2 analyses were instead performed using 197, 105, and 103 
entries, respectively.
Secondary structure probabilities for the individual structures 
were normalized according to the relative CDR length. They 
were calculated using DSSP (34) for each of the six CDR regions 
(Chothia definition) (1, 35) in the kappa and lambda datasets. 
The DSSP algorithm assigns secondary structure to residues 
according to a hydrogen-bond definition with an energy cut-off 
of less than −0.5 kcal mol−1 (34). The DSSP output was recorded 
as follows: extended β-strands and β-bridges as “Beta”; α-helices, 
310-helices, and π-helices as “Helix”; 3, 4, and 5 turns and non-
hydrogen bonded bends as “Turn”; and random coil as “Coil.”
Mean probability values and error bars were calculated using 
a bootstrapping method [boot() function in R] to generate 100 
randomly resampled subsets for each of the reference datasets. 
Error bars were computed as the 95% confidence intervals of 
the bootstrapped distributions. This permitted estimates of the 
accuracies of the calculations and avoided any biases resulting 
from dataset selection.
resUlTs
lambda cDr-l3 regions are significantly 
longer and More hydrophobic than Kappa 
cDr-l3 regions
Figure  1A shows cumulative frequency histograms of the 
length, hydrophobicity [GRAVY (36) and Boman (37) indices], 
aliphatic index (38), and isoelectric point (pI) (39) of kappa 
and lambda CDR-L3 regions of the antibody repertoires from 
each cell type (immature, transitional, and naïve). In each case, 
the lambda CDR-L3 regions are significantly longer, more 
hydrophobic, and have a higher aliphatic index than kappa 
CDR-L3 regions (p <  0.0001; KS test). It was also found, in 
all three cell types, that lambda light chains have lower pIs on 
average than kappa light chains (see Supplementary Table 2 in 
the Supplementary Data Sheet for mean values, SD, and 95% 
confidence intervals of all CDR-L3 properties measured). Both 
kappa and lambda repertoires show a “step change” in cumula-
tive frequency at pI 6.08–6.10 due to the very high frequency 
of occurrence of this characteristic in both repertoires. We also 
looked at the same physicochemical properties of the CDR-L1 
and CDR-L2 amino acid sequences and found significant differ-
ences between the kappa and lambda isotypes (Supplementary 
Figure 1 in the Supplementary Data Sheet). Within the same 
light chain isotype, there were sometimes small differences 
in the distributions of CDR properties between the different 
immature/transition/naïve cell types, although these differ-
ences were negligible in comparison to the large differences 
between kappa and lambda isotypes. We therefore pooled the 
data from all three cell types (into “kappa” and “lambda”) for 
subsequent analyses.
We also looked at the frequency of various classes of 
amino acids in the CDR-L3 regions. Amino acids were clas-
sified by their properties as follows (25): tiny (ACGST), small 
(ABCDGNPSTV), aliphatic (AILV), aromatic (FHWY), non-
polar (ACFGILMPVWY), polar (DEHKNQRSTZ), charged 
(BDEHKRZ), basic (HKR), and acidic (BDEZ). Figure 1B shows 
that the amino acid composition of the CDR-L3 regions is signifi-
cantly different between kappa and lambda [multiple t-tests and 
FDR correction (Q = 1%)].
Differences between Kappa and lambda 
cDr-l3 Properties are encoded in the 
germline
The CDR-L3 region is encoded by germline IGLV/J genes together 
with a small number of non-germline nucleotides added by the 
TdT enzyme. We found that the mean number of N nucleotide 
additions by TdT, as reported by IMGT HighV-QUEST, was 
slightly higher in lambda than kappa (lambda mean =  3.321, 
95% CI [3.204, 3.438] and kappa mean = 3.046, 95% CI [2.990, 
3.102]). Interestingly, we observed that the mean number of N 
additions per donor showed a significant positive correlation 
between kappa and lambda loci (Figure 2A). Furthermore, the 
mean number of kappa/lambda light chain N additions per donor 
was also significantly positively correlated with the mean number 
of heavy chain N additions in the same donor (Figure 2A). This 
may indicate that TdT works with differing efficiencies between 
FigUre 1 | Physicochemical properties of kappa and lambda cDr-l3 amino acid sequences. (a) Cumulative frequency histograms of a number of 
physicochemical properties of the kappa (red) and lambda (blue) CDR-L3 regions for each cell type (immature, transitional, and naïve). In every case, the 
distributions of the kappa and lambda repertoires for each cell type were significantly different (p < 0.0001, Kolmogorov–Smirnov test). (B) The mean frequency of 
usage in kappa and lambda CDR-L3 regions of each amino acid class (as described in the table). All cell types were pooled together. Tiny, non-polar, aliphatic, 
charged, and acidic amino acids are more frequently used in lambda CDR-L3 regions, whereas polar, aromatic, and basic amino acids are more frequently used in 
kappa CDR-L3 regions. Multiple t-tests were performed, followed by false discovery rate (FDR) correction for multiple testing (Q = 1%); an asterisk (*) indicates a 
discovery. Error bars indicate 1 SD.
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different people, but the same efficiency in the different classes of 
immunoglobulin chain. Mean N addition was not significantly 
correlated with the age of the donor (data not shown). The mean 
kappa, lambda, and heavy chain N addition differed by as much 
as 2.5, 4.3, and 3 nucleotides, respectively, between some donors, 
indicating an approximate difference of 1 non-germline-encoded 
CDR3 amino acid.
Due to the small number of N additions, and the contribution 
to the CDR-L3 codons from IGLV and IGLJ genes, the precise 
effect of N addition/deletion on the amino acid content at the 
CDR-L3 region cannot be assessed in order to accurately measure 
any qualitative effect due to TdT/exonuclease activity. Therefore, 
we concentrated on the amino acid contribution to CDR-L3 
from the germline IGLV and IGLJ sequences. To achieve this, we 
built a dataset that is composed of theoretical “germline CDR-
L3” regions, where IMGT germline IGLV and IGLJ amino acid 
sequences were combined and represented at the same frequency 
with which they occurred in the real dataset.
Figure 2B shows the theoretical “germline CDR-L3” phys-
icochemical properties plotted against the physicochemical 
FigUre 2 | investigating the effect of n nucleotide addition and germline sequences. (a) The mean N nucleotide addition per donor (all cell types) 
(N = number of donors). Spearman’s rank correlation coefficient (r) and two-tailed p values (p) show that N nucleotide addition is positively correlated between 
kappa, lambda, and heavy chain CDR3 regions. (B) Physicochemical properties of theoretical “germline CDR-L3” regions (constructed using IMGT sequences) 
plotted alongside the physicochemical properties of the real CDR-L3 sequences (all cell types). The distributions of the real and IMGT datasets were significantly 
different for every property measured (p < 0.0001, Kolmogorov–Smirnov test). A cumulative frequency histogram for the CDR-L3 length could not be plotted 
because kappa “germline CDR-L3” regions were all 9 amino acids long; on average, the real kappa CDR-L3 regions were 9.20 amino acids long, and the lambda 
real and “germline” were 10.48 and 10.83 amino acids long, respectively.
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properties of the real dataset. The differences between kappa 
and lambda are still clearly visible in the theoretical germline 
dataset, indicating that these physicochemical differences 
are mostly encoded in the germline. We can see differences 
between the real and theoretical datasets, implying that 
nucleotide addition/deletion does have a significant effect 
on the physicochemical properties of the CDR-L3 region, 
although palindromic (P) nucleotide addition would also con-
tribute to this difference. The effect of the addition/deletion of 
nucleotides is not consistent between kappa and lambda genes 
(i.e., the difference between kappa and lambda in the germline 
dataset is not consistently bigger or smaller than in the real 
dataset).
Kappa and lambda isotypes are 
separated by Pca Using cDr-l3 region 
Kidera Factors
Kidera factors are a set of 10 factors, which describe orthogonal 
physicochemical protein properties that are related to protein 
structure (27, 40). Figure 3 shows a PCA conducted using the 10 
Kidera factors for the CDR-L3 region of each of the 20,571 kappa 
sequences and 8,876 lambda sequences. Principal component 1 
(PC1) splits the kappa and lambda isotypes into two clusters. The 
Kidera factors that were best correlated with PC1 were Factor 10 
(surrounding hydrophobicity), Factor 2 (side-chain size), and 
Factor 7 (flat extended preference) (41). The cumulative frequency 
FigUre 3 | Principal component analysis (Pca) using Kidera factors of the light chain cDr-l3 amino acid sequences. PCA was performed using the 
Kidera factor vectors 1–10 of each kappa (red, N = 20,571) and lambda (blue, N = 8,876) CDR-L3 amino acid sequence. PC1 shows separation of the kappa and 
lambda isotypes. The Kidera factors that were most correlated with PC1 are Kidera 10, Kidera 2, and Kidera 7.
7
Townsend et al. Kappa and Lambda CDR3 Regions
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 388
distributions of kappa and lambda CDR-L3 Kidera factors can 
be found in Supplementary Figure 2 in the Supplementary Data 
Sheet.
Some separation of the kappa and lambda isotypes can be 
seen when applying PCA to CDR-L1 and CDR-L2; however, the 
separation is not as clear as it is in the CDR-L3 region (data not 
shown).
The Distributions of cDr-h3 Properties  
in Kappa and lambda antibodies  
are not consistently Different
To investigate whether the use of kappa or lambda is associated 
with particular heavy chain properties, we measured a variety of 
physicochemical properties of CDR-H3 amino acid sequences 
obtained from the paired heavy–light chain variable region 
sequences of naïve B cells from three donors (20) and compared 
the values from heavy chains paired with kappa light chains to 
heavy chains paired with lambda light chains (see Supplementary 
Figure 3 in the Supplementary Data Sheet for cumulative fre-
quency plots, which confirm that the light chain isotypes of this 
published dataset separate in the same way as those from our 
dataset, as shown in Figure 1A). To account for donor variability, 
we plotted the kappa and lambda antibody CDR-H3 repertoires 
of each donor separately (Figure  4A). We then compared the 
kappa and lambda CDR-H3 property distributions for each 
donor individually using the KS test. We found that for many of 
the properties (e.g., GRAVY index, Boman index, and aliphatic 
index), there was no significant difference between the repertoires 
for any of the donors. However, we did find that for Donor 2, the 
lambda repertoire CDR-H3 regions were significantly shorter 
than the kappa repertoire, and for Donors 1 and 2, we found that 
the lambda repertoire had a significantly lower CDR-H3 pIs than 
the kappa repertoire. We also looked at IGHV-D-J family usage in 
the kappa and lambda repertoires of the three donors (Figure 4B) 
and found no significant difference in frequency [multiple t-tests 
FigUre 4 | The cDr-h3 physicochemical properties and ighV-D-J usage of heavy chains paired with kappa or lambda light chains. (a) Cumulative 
frequency histograms of CDR-H3 physicochemical properties of kappa and lambda antibodies. Each donor is plotted separately. Statistical significance for each 
donor was calculated using the Kolmogorov–Smirnov test. D1, D2, and D3 refer to Donor 1, Donor 2, and Donor 3, respectively. (B) Mean frequency of IGHV-D-J 
family usage across the three donors. Error bars show ±1 SD.
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and FDR correction (Q = 1%)]. The small differences in CDR-H3 
physicochemical properties appear to be donor-specific with no 
overarching effects. This leads us to believe that despite the large 
differences between kappa and lambda CDR-L3 physicochemi-
cal properties, heavy–light chain pairing is virtually random, 
although there may be some very subtle biases which are specific 
to individuals.
Kappa and lambda antibodies  
are structurally Different
Figure 3 showed that Kidera factors, which are related to protein 
structure, separate the kappa and lambda isotypes well. This 
raised the question: how do the kappa and lambda isotypes influ-
ence the light chain structure?
To investigate this, we extracted two datasets of antibody 
structures from the PDB split according to light chain isotype 
(kappa or lambda) and calculated the secondary structure 
occupancies of the light chain CDR regions for each dataset 
(Figure 5). We found that the beta structure content of kappa 
light chains was significantly higher than lambda light chains in 
the CDR-L1 and -L2 regions but significantly lower in CDR-L3 
regions (Figure 5A). Differences in beta structure content were 
compensated for by changes in coil structure content in the 
CDR-L2 and -L3 regions and, surprisingly, by changes in the 
helix structure content of the CDR-L1. In this context, significant 
differences in turn structure (which included 3, 4, and 5 turns 
and non-hydrogen-bonded bends) were not meaningful as these 
conformational states serve to link more regular secondary 
FigUre 5 | Probability of encountering various secondary structures in antibody heavy and light chain cDr regions. The graphs show the mean 
proportion of residues in the CDR loops, which are conforming to each of the following groups of secondary structures: beta, coil, helix, or turn. The error bars 
represent the confidence intervals at the 95% level, estimated using 100 runs of bootstrap resampling. (a) All the three light chain CDR regions show differences 
between the kappa and lambda isotypes in the proportion of the CDR regions that are composed of four secondary structures (beta, coil, helix, and turn). (B) The 
only significant difference between kappa and lambda in the composition of heavy chain CDR regions was in the frequency of helix structure in the CDR-H2 region. 
Differences were considered significant if the 95% CIs did not overlap.
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structure types, beta sheets and helices alike. We postulated that 
secondary structure probabilities could be influenced by CDR 
length with, for example, shorter polypeptide regions favoring 
more ordered secondary structures. However, secondary struc-
ture probabilities did not appear to correlate with CDR length 
(data not shown). The secondary structure propensities of heavy 
chain CDR regions were also compared; however, the only 
significant difference observed between heavy chain partners of 
the kappa and lambda light chain isotypes was the proportion 
of helix in CDR-H2 (Figure 5B). Otherwise, in agreement with 
the result in Figure 4, all other properties were not significantly 
different.
DiscUssiOn
In this paper, we have shown that kappa and lambda CDR-L3 
regions differ significantly in their physicochemical properties, 
indicating that kappa and lambda light chains may have differing 
roles in antibody binding.
In accordance with previous publications, we found that 
lambda CDR-L3 regions are, on average, significantly longer and 
more hydrophobic than kappa (20), and, in addition, we found 
that lambda CDR-L3 regions have a higher aliphatic index than 
kappa CDR-L3 regions. In the case of heavy chains, long hydro-
phobic CDR-H3 regions are selected against as B cells mature 
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and pass through tolerance checkpoints (42–44) (and data not 
shown), and it is thought that these properties in heavy chains are 
associated with autoreactivity (45). However, despite their longer, 
hydrophobic qualities, lambda light chains have been reported 
to be better at removing a polyspecific antibody phenotype than 
kappa in vitro (17). Since, in vivo, the lambda locus is rearranged 
after the kappa locus (13), lambda light chains are perhaps likely 
to have a role in “rescuing” antibodies that were autoreactive 
when the same heavy chain was paired with a kappa light chain. 
The apparent contradiction between proposed roles of longer 
hydrophobic CDR3 regions in heavy vs. light chains may indicate 
that CDR-L3 and CDR-H3 regions have different roles to play in 
the structure of the antigen-binding site.
Both kappa and lambda isotypes had a very high frequency of 
CDR-L3 regions with pI of between 6.08 and 6.10. A similar pattern 
is also seen in the heavy chain repertoire in our data (not shown) 
and Figure  4A. This suggests that a slightly acidic CDR-L3 pI 
(net negative charge at neutral pH) is highly advantageous in the 
antibody repertoire and that a CDR-L3 pI of approximately 7.00 
(net neutral charge at neutral pH) is less so, as very few sequences 
of either isotype have a neutral CDR-L3 pI. It has been suggested 
that a more basic CDR-H3 pI may be associated with polyspeci-
ficity (46). Since lambda CDR-L3 regions had a lower mean pI 
and higher acidic amino acid usage than kappa (Figure 1), the 
aforementioned ability of lambda light chains to rescue polyspe-
cific antibodies may be a result of this charge-related phenotype. 
Light chains with a low CDR pI, or high aspartic acid usage, have 
been shown to be good at rescuing DNA-reactive heavy chains 
(47, 48). This may be because DNA has a high negative charge; 
so, reducing the positive charge of an antibody by changing the 
light chain for one with more acidic character could help abolish 
inappropriate ionic interactions.
Another possibility to account for a functional difference 
in kappa and lambda light chains is not that they evolved to 
bind to different types of antigen, but that they have evolved to 
respond in different ways to antigen. Codon usage in kappa and 
lambda light chains leads to quite different affinity maturation 
patterns as a result of somatic hypermutation; codons encoding 
the kappa CDRs are prone to more non-conservative mutations 
than lambda; however, this is also more likely to result in stop 
codons (49). So, the consequences of somatic hypermutation for 
kappa and lambda may be quite different, and this could provide 
a useful extra level of diversity in response to different antigenic 
challenges.
The kappa/lambda CDR-L3 physicochemical differences that 
we observed are mostly encoded in the germline, and since it is 
thought that light chains diverged into isotypes more than 450 
million years ago, these differences are the result of millennia of 
evolution (50). Other species vary with respect to antibody light 
chains. Bony fish and amphibians are endowed with three distinct 
light chain isotypes (kappa, lambda, and sigma), whereas mam-
mals and reptiles only possess two (kappa and lambda). The kappa 
light chain has been lost in birds, leaving only the lambda light 
chain (51, 52), and camelids have been found to have antibody 
classes which lack light chains completely (53). This disparity 
in light chains between species indicates that having two light 
chain isotypes is not essential for a fully functioning antibody 
repertoire. However, the fact that camelid heavy chain antibodies 
require alternative mechanisms of antibody diversification in the 
absence of light chains indicates that the additional variability 
that light chains enable is advantageous (54). Recent work in the 
study of allergy has also highlighted a potential role for free light 
chains in the antigen-specific activation of mast cells (55).
The N nucleotide addition in light chain CDR-L3 regions is 
quite limited, but we did see that lambda light chains have a slightly 
higher mean N addition than kappa. What was most striking was 
a significant positive correlation of mean N addition between the 
kappa, lambda, and heavy chain CDR3 regions within individu-
als, even though there was a mean difference of approximately 
three non-germline-encoded N nucleotides in the CDR3 regions 
between some people. We hypothesize that this may be due to 
individual variation in the efficiency of the N nucleotide addition 
process. It would be interesting to investigate whether variation 
in N nucleotide addition affects the humoral immune response.
Heavy–light chain pairing is a subject of great interest, with 
some groups reporting small biases in pairing (56), whereas oth-
ers report that the heavy–light chain pairing is not significantly 
different to that which would be expected if it were random (20, 
57). These studies have looked at heavy and light chain V(D)J 
pairings, whereas we looked at CDR3 physicochemical proper-
ties. Overall, we only found a few, donor-specific, significant 
differences in the distributions of CDR-H3 properties of heavy 
chains paired with kappa and lambda light chains. Our study 
supports a hypothesis for virtually random heavy–light chain 
pairing, although certain small biases can occasionally be seen 
within individuals.
Structural differences in the CDR loops of kappa and lambda 
antibodies have been noted previously, notably that the major-
ity (approximately 80%) of kappa CDR-L3 loops have the same 
canonical structure, whereas lambda CDR-L3 loops can adopt a 
plethora of canonical structures (58). When analyzing the mean 
proportions of light chain CDR regions adopting specific second-
ary structures, we found significant differences between kappa and 
lambda (Figure 5A). In particular, we found that the likelihood 
of beta structure content was significantly higher in kappa CDR-
L1 and -L2 regions but significantly lower in CDR-L3 regions 
when compared to lambda light chains. Moreover, we found that 
differences in the frequency of beta propensity in CDR-L1 and 
-L2 tended to be compensated for by higher frequencies of helix 
and coil propensities, respectively, in the lambda isotype. In the 
CDR-L3 region, there were significant differences between kappa 
and lambda propensities for beta, coil, and turn structures.
To date, much attention has been paid to the role of the heavy 
chain CDR-H3 region in antibody binding, and the contribution 
of the light chain to antibody-binding specificity has sometimes 
been overlooked. Our findings show that there are significant 
differences in kappa and lambda light chains and lend further 
support to a growing body of evidence that they may have differ-
ent roles in the adaptive immune response.
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